Roche Wants More Flexibility For UK’s NICE To Consider Indication-Based Pricing
Executive Summary
Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.
You may also be interested in...
UK NICE Changes Mind On Ocrevus After Roche Drops Price
Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.
Pharma Q3 Results Preview: J&J, Novartis & Roche
Investors are keen to see how J&J's Remicade is holding up to biosimilar competition, especially now that Zytiga generics are on the way. Novartis is likely to play up the potential for new launches like siponimod in multiple sclerosis and Aimovig in migraine, while Roche is expected to continue delivering strong performance for core brands and expansion plans for Tecentriq.
Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus
After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.